Skip to menu Skip to content Skip to footer
Dr Andrew Burke
Dr

Andrew Burke

Email: 

Overview

Background

Dr Andrew Burke currently works with the UQ Centre for Clinical Research, The University of Queensland and is dual specialist in both infectious diseases and thoracic medicine at The Prince Charles Hospital, Brisbane. He has diverse clinical experience in low income countries and regional Australia and holds a Diploma in Tropical Medicine and Hygiene (Liverpool) and a Masters in Public Health from the University of Queensland.

Andrew is a principal investigator on a number of industry lead trials for pulmonary NTM infection. He is an associate investigator on the FORMAT study assessing clinical outcomes in pulmonary Mycobacterium abscessus infection and with Professor Jason Roberts of UQCCR is leading the pharmacokinetic sub-studies in this multi-national trial.

Andrew is on the Australian Therapeutic Guidelines writing groups for both antibiotics and respiratory disease. He is current chair of the steering committee of the Australasian Clinical Tuberculosis network (ACTnet) and is on the Queensland Tuberculosis Expert Advisory Group. He is currently undertaking a PhD in the pharmacokinetics of mycobacterial drugs in people with tuberculosis and cystic fibrosis. As part of his PhD he is exploring the role of therapeutic drug montioring in complex mycobacterial infections and sees great potential for Australian and Asia-Pacific researchers to contribute to mycobacterial research through involvement in PK studies.

Availability

Dr Andrew Burke is:
Available for supervision

Works

Search Professor Andrew Burke’s works on UQ eSpace

59 works between 2011 and 2026

1 - 20 of 59 works

2026

Journal Article

Cutaneous Mycobacterium haemophilum infection in an immunosuppressed host: a case report of diagnostic considerations and microbiologic confirmation

Lane, Angus, Godbolt, Amanda, Morton, Sarah, Wiseby, Heather, Menon, Vivek, Coulter, Chris, Pandey, Sushil and Burke, Andrew (2026). Cutaneous Mycobacterium haemophilum Infection in an Immunosuppressed Host: A Case Report of Diagnostic Considerations and Microbiologic Confirmation. Clinical Case Reports, 14 (7) e73131. doi: 10.1002/ccr3.73131

Cutaneous Mycobacterium haemophilum infection in an immunosuppressed host: a case report of diagnostic considerations and microbiologic confirmation

2026

Journal Article

Cerebrospinal Fluid Concentrations of Bedaquiline, Pretomanid, and Linezolid During Curative Treatment of Fluoroquinolone-Resistant Pre–Extensively Drug-Resistant Tuberculous Meningitis

Tramontana, Adrian Robert, Burke, Andrew, Globan, Maria, McWhinney, Brett, Bloch, Aaron E, Smith, Benjamin J, Denholm, Justin T, Wright, Connor James and Molton, James S (2026). Cerebrospinal Fluid Concentrations of Bedaquiline, Pretomanid, and Linezolid During Curative Treatment of Fluoroquinolone-Resistant Pre–Extensively Drug-Resistant Tuberculous Meningitis. Open Forum Infectious Diseases, 13 (7) ofag445, 7. doi: 10.1093/ofid/ofag445

Cerebrospinal Fluid Concentrations of Bedaquiline, Pretomanid, and Linezolid During Curative Treatment of Fluoroquinolone-Resistant Pre–Extensively Drug-Resistant Tuberculous Meningitis

2026

Journal Article

Non-antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis – A systematic review

Burke, Andrew, Jahnke, Nikki, Smith, Sherie, Smyth, Alan R, Stewart, Iain, Tillman, Laura and Nick, Jerry A (2026). Non-antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis – A systematic review. Journal of Cystic Fibrosis, 25 (2), 248-256. doi: 10.1016/j.jcf.2025.12.014

Non-antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis – A systematic review

2026

Other Outputs

The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection

Burke, Andrew (2026). The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection. PhD Thesis, UQ Centre for Clinical Research, The University of Queensland. doi: 10.14264/9518e78

The Pharmacokinetics & Pharmacodynamics of Antimycobacterial Drugs in People with Cystic Fibrosis and Drug-Resistant Tuberculosis Infection

2026

Journal Article

Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD)

Kang, Shaun J. W., Watt, Adrian, Wilson, Malcolm R., Eather, Geoffrey W., Baird, Timothy, Evans, Ieuan E. S., Burke, Andrew J. and Thomson, Rachel M. (2026). Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD). Mycobacteria, 2 (1) 1. doi: 10.1186/s44350-026-00012-1

Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD)

2026

Journal Article

A successful lung transplantation in a patient with active coronavirus disease 2019: a case report

Divithotawela, Chandima, Lee, Zhenhui Shawn, Hopkins, Peter Mark Anthony, Burke, Andrew and Fiene, Andreas (2026). A successful lung transplantation in a patient with active coronavirus disease 2019: a case report. Transplantation Proceedings, 58 (2), 378-380. doi: 10.1016/j.transproceed.2025.12.016

A successful lung transplantation in a patient with active coronavirus disease 2019: a case report

2025

Journal Article

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard

Evans, Ieuan Edward Shepherd, Smith, Daniel, Henderson, Daniel, Riddles, Timothy, Masel, Philip, Moore, Vanessa, Burke, Andrew J., Thomson, Rachel M. and Reid, David W. (2025). Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. BMJ Open Respiratory Research, 12 (1) e003204, 1-9. doi: 10.1136/bmjresp-2025-003204

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard

2025

Journal Article

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates

Patterson-Fahy, Kirby, Carter, Robyn, Bell, Scott C., Evans, Ieuan E. S., Burke, Andrew John and Thomson, Rachel M. (2025). In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. Journal of Antimicrobial Chemotherapy, 81 (1) dkaf441, 1-9. doi: 10.1093/jac/dkaf441

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates

2025

Journal Article

Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial

Jong, Tiffany, Baird, Timothy, Barr, Helen Louise, Bell, Scott, Bigirumurame, Theophile, Brady, Kara, Burke, Andrew, Byrnes, Joshua, Caudri, Daan, Clark, Julia E., Coin, Lachlan J.M., Goh, Felicia, Grimwood, Keith, Hicks, Daniel, Jayawardana, Kaushala, Joshi, Sri, Lee, Katherine, Qvist, Tavs, Reid, David, Rice, Megan, Roberts, Jason A., Rogers, Geraint, Shackleton, Claire, Sly, Peter D., Smyth, Alan R., Stevens, Luke, Stockwell, Rebecca, Tarique, Abdullah, Taylor, Steven ... Wainwright, Claire (2025). Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial. BMJ Open, 15 (9) e096188, 1-16. doi: 10.1136/bmjopen-2024-096188

Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial

2025

Conference Publication

Development of quantitative CT image analysis for NTM lung disease interventions

Makani, Punitkumar, Mollica, Federico, Bonte, Merlijn, Burke, Andrew, Hicks, Daniel, Thomson, Rachel, Wainwright, Claire, Tiddens, Harm and Caudri, Daan (2025). Development of quantitative CT image analysis for NTM lung disease interventions. European-Respiratory-Society Congress (ERS), Amsterdam Netherlands, Sep 27-Oct 01, 2025. SHEFFIELD: EUROPEAN RESPIRATORY SOC JOURNALS LTD. doi: 10.1183/13993003.congress-2025.PA3971

Development of quantitative CT image analysis for NTM lung disease interventions

2025

Conference Publication

Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial

Wainwright, C., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.118

Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial

2025

Conference Publication

Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial

Wainwright, C., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.119

Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial

2025

Journal Article

Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy

Wolie, Zenaw T., Unwin, Sean, Burke, Andrew, Won, Hayoung, Wallis, Steven C., Seaton, R Andrew, Gilchrist, Mark, Roberts, Jason A. and Sime, Fekade B. (2025). Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. JAC - Antimicrobial Resistance, 7 (3) dlaf074, dlaf074. doi: 10.1093/jacamr/dlaf074

Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy

2025

Conference Publication

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

Twining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444

Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease

2025

Conference Publication

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7277

Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial

2025

Conference Publication

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

Thomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. ATS International Conference, San Francisco, CA, United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7278

Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial

2025

Journal Article

Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19

Roberts, Darren M., Liu, Xin, Parker, Suzanne L., Burke, Andrew, Peek, Jenny, Carland, Jane E., Murnion, Bridin, Seah, Vincent, Wallis, Steven C., Sumi, Chandra D., Pandey, Saurabh, Buscher, Hergen, Byrne, Anthony, Sandaradura, Indy, Bowen, David, Holz, Simon, Stewart, Adam G., Hajkowicz, Krispin M. and Roberts, Jason A. (2025). Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19. Clinical Pharmacokinetics, 64 (5) e0022222, 743-756. doi: 10.1007/s40262-025-01496-2

Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19

2025

Journal Article

A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infection

Thomson, Rachel M., Burke, Andrew J., Morgan, Lucy C. and Colin, Andrew A. (2025). A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infection. Annals of the American Thoracic Society, 22 (7), 1092-1097. doi: 10.1513/annalsats.202407-745rl

A pilot study to assess the effect of intermittent inhaled nitric oxide as treatment of nontuberculous mycobacteria lung infection

2025

Conference Publication

Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial

Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons.

Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial

2025

Journal Article

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

Mou, Claire Y., Henderson, Daniel J., Matson, Angela G., Herd, Karen M., Reid, David W., Riddles, Timothy, Johnson, Ellie, McWhinney, Brett, Swenson, Rebecca, Burke, Andrew and Evans, Ieuan E.S. (2025). The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease. European Clinical Respiratory Journal, 12 (1) 2458341, 1-5. doi: 10.1080/20018525.2025.2458341

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

Funding

Current funding

  • 2024 - 2028
    Unlocking the gut microbiome to track the spread of AMR genes and pathogens
    MRFF - Global Health Initiative
    Open grant
  • 2019 - 2026
    Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMAT)
    Cystic Fibrosis Foundation USA
    Open grant

Past funding

  • 2018 - 2019
    Study of Prescribing patterns and Effectiveness of Ceftolozane-Tazobactam: Real -world Analysis (SPECTRA)
    Merck Sharp & Dohme Australia
    Open grant

Supervision

Availability

Dr Andrew Burke is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Dr Andrew Burke's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au